Skip to main content
. Author manuscript; available in PMC: 2017 Jan 24.
Published in final edited form as: J Natl Cancer Inst. 2007 Oct 30;99(21):1623–1633. doi: 10.1093/jnci/djm198

Fig. 4.

Fig. 4

In vivo efficacy of systemically administered Seneca Valley Virus-001 (SVV-001). A single intravenous injection of saline vehicle or SVV-001 at the indicated doses (virus particles per kg) was given to athymic mice bearing preestablished xenograft tumors on study day 1 (denoted by ↑). A) Human small-cell lung tumor line, H446 (n = 10 per group). B) Human retinoblastoma Y79 (n = 7–8 per group). Mean tumor volumes and 95% confidence intervals are plotted as a function of time. *, P <.01 (two-sided, calculated using Dunnett’s test) compared with saline control for all SVV-001-treated groups with mean values appearing below the asterisk in the figure. C) Survival curves of nude mice bearing xenografts of the human retinoblastoma tumor line Y79. *, P <.001 (two-sided, calculated using the log-rank test) compared with saline control.